Monoclonal antibody G250RIT

N/A

Report date: 2022/03/17 14:31:29

Base Information

Drug NameMonoclonal antibody G250RIT
Drug Alias NameWX-G250RIT
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionIonising radiation emittersAnti-Carbonic anhydrase IX
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsBiliary Tract NeoplasmsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Innovative MedicineWilex AG
Active IndicationsN/A
Inactive IndicationsBiliary Tract NeoplasmsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A